Cargando…

Evaluation of ABCA1 gene polymorphism as a prognostic index of fibrosis progression in NAFLD patients

INTRODUCTION: It had been evident that non‐alcoholic fatty liver disease (NAFLD) is the new era epidemic. Despite emergence of many drugs on the pipeline that considered candidates to cure NAFLD/NASH, the critical need for defining the cohort liable to fibrosis progression is yet unmet. AIM: Evaluat...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghanem, Samar E., Elsabaawy, Maha M., Abdelkareem, Mervat M., Helal, Marwa L., Othman, Warda, Elsayed, Mahitab, Elsabaawy, Dalia M., El Fert, Ashraf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9836255/
https://www.ncbi.nlm.nih.gov/pubmed/36444680
http://dx.doi.org/10.1002/edm2.394
_version_ 1784868824454004736
author Ghanem, Samar E.
Elsabaawy, Maha M.
Abdelkareem, Mervat M.
Helal, Marwa L.
Othman, Warda
Elsayed, Mahitab
Elsabaawy, Dalia M.
El Fert, Ashraf
author_facet Ghanem, Samar E.
Elsabaawy, Maha M.
Abdelkareem, Mervat M.
Helal, Marwa L.
Othman, Warda
Elsayed, Mahitab
Elsabaawy, Dalia M.
El Fert, Ashraf
author_sort Ghanem, Samar E.
collection PubMed
description INTRODUCTION: It had been evident that non‐alcoholic fatty liver disease (NAFLD) is the new era epidemic. Despite emergence of many drugs on the pipeline that considered candidates to cure NAFLD/NASH, the critical need for defining the cohort liable to fibrosis progression is yet unmet. AIM: Evaluate ABCA1 (rs1800977) genotyping as a noninvasive predictor of liver fibrosis severity. MATERIALS AND METHODS: This study included 118 liver biopsy‐proven NAFLD‐patients. According to Metavir‐fibrosis‐staging, cases were divided to early fibrosis (74 cases), and 44 cases with significant fibrosis (>F2), added to 49 healthy control subjects. All patients were subjected to liver function tests, lipids profile, triglyceride TG index, and hepatic steatosis index (HSI) and real‐time PCR ABCA1 SNP (rs1800977). RESULTS: Significant differences in transaminases (p > .05), albumin (p < .009), cholesterol (p0.03), low density lipoproteins (LDL) (0.006), triglycerides (p < .001), HSI (p < .001), FIB4 (p < .001) and APRI (p < .001) were reported in those with significant than early fibrosis and control groups. CC was the most prevalent in significant (36.4%) than early fibrosis (13.5%) and control groups (8.2%), with prevalence of C allele in significant fibrosis (p ≤ .003). Univariate analysis revealed that DM (p ≤ .001), TG index (p ≤ .022), cholesterol (p ≤ .03), HSI (p ≤ .006), LDL (p ≤ .02), HDL (p ≤ .01), APRI (p ≤ .02) and CC genotype (p ≤ .005) were the main factors affecting fibrosis progression in NAFLD. However multivariate analysis proved only the role of HSI (p ≤ .005), LDL (p ≤ .02), HDL (p ≤ .003) and CC genotype (p ≤ .03) in predicting fibrosis severity. CONCLUSION: Dyslipidemias, hepatic steatosis index and ABCA1 (rs1800977) gene polymorphism CC genotype; were the only independent predictors of advanced fibrosis in NAFLD‐patients.
format Online
Article
Text
id pubmed-9836255
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-98362552023-01-18 Evaluation of ABCA1 gene polymorphism as a prognostic index of fibrosis progression in NAFLD patients Ghanem, Samar E. Elsabaawy, Maha M. Abdelkareem, Mervat M. Helal, Marwa L. Othman, Warda Elsayed, Mahitab Elsabaawy, Dalia M. El Fert, Ashraf Endocrinol Diabetes Metab Research Articles INTRODUCTION: It had been evident that non‐alcoholic fatty liver disease (NAFLD) is the new era epidemic. Despite emergence of many drugs on the pipeline that considered candidates to cure NAFLD/NASH, the critical need for defining the cohort liable to fibrosis progression is yet unmet. AIM: Evaluate ABCA1 (rs1800977) genotyping as a noninvasive predictor of liver fibrosis severity. MATERIALS AND METHODS: This study included 118 liver biopsy‐proven NAFLD‐patients. According to Metavir‐fibrosis‐staging, cases were divided to early fibrosis (74 cases), and 44 cases with significant fibrosis (>F2), added to 49 healthy control subjects. All patients were subjected to liver function tests, lipids profile, triglyceride TG index, and hepatic steatosis index (HSI) and real‐time PCR ABCA1 SNP (rs1800977). RESULTS: Significant differences in transaminases (p > .05), albumin (p < .009), cholesterol (p0.03), low density lipoproteins (LDL) (0.006), triglycerides (p < .001), HSI (p < .001), FIB4 (p < .001) and APRI (p < .001) were reported in those with significant than early fibrosis and control groups. CC was the most prevalent in significant (36.4%) than early fibrosis (13.5%) and control groups (8.2%), with prevalence of C allele in significant fibrosis (p ≤ .003). Univariate analysis revealed that DM (p ≤ .001), TG index (p ≤ .022), cholesterol (p ≤ .03), HSI (p ≤ .006), LDL (p ≤ .02), HDL (p ≤ .01), APRI (p ≤ .02) and CC genotype (p ≤ .005) were the main factors affecting fibrosis progression in NAFLD. However multivariate analysis proved only the role of HSI (p ≤ .005), LDL (p ≤ .02), HDL (p ≤ .003) and CC genotype (p ≤ .03) in predicting fibrosis severity. CONCLUSION: Dyslipidemias, hepatic steatosis index and ABCA1 (rs1800977) gene polymorphism CC genotype; were the only independent predictors of advanced fibrosis in NAFLD‐patients. John Wiley and Sons Inc. 2022-11-29 /pmc/articles/PMC9836255/ /pubmed/36444680 http://dx.doi.org/10.1002/edm2.394 Text en © 2022 The Authors. Endocrinology, Diabetes & Metabolism published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Articles
Ghanem, Samar E.
Elsabaawy, Maha M.
Abdelkareem, Mervat M.
Helal, Marwa L.
Othman, Warda
Elsayed, Mahitab
Elsabaawy, Dalia M.
El Fert, Ashraf
Evaluation of ABCA1 gene polymorphism as a prognostic index of fibrosis progression in NAFLD patients
title Evaluation of ABCA1 gene polymorphism as a prognostic index of fibrosis progression in NAFLD patients
title_full Evaluation of ABCA1 gene polymorphism as a prognostic index of fibrosis progression in NAFLD patients
title_fullStr Evaluation of ABCA1 gene polymorphism as a prognostic index of fibrosis progression in NAFLD patients
title_full_unstemmed Evaluation of ABCA1 gene polymorphism as a prognostic index of fibrosis progression in NAFLD patients
title_short Evaluation of ABCA1 gene polymorphism as a prognostic index of fibrosis progression in NAFLD patients
title_sort evaluation of abca1 gene polymorphism as a prognostic index of fibrosis progression in nafld patients
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9836255/
https://www.ncbi.nlm.nih.gov/pubmed/36444680
http://dx.doi.org/10.1002/edm2.394
work_keys_str_mv AT ghanemsamare evaluationofabca1genepolymorphismasaprognosticindexoffibrosisprogressioninnafldpatients
AT elsabaawymaham evaluationofabca1genepolymorphismasaprognosticindexoffibrosisprogressioninnafldpatients
AT abdelkareemmervatm evaluationofabca1genepolymorphismasaprognosticindexoffibrosisprogressioninnafldpatients
AT helalmarwal evaluationofabca1genepolymorphismasaprognosticindexoffibrosisprogressioninnafldpatients
AT othmanwarda evaluationofabca1genepolymorphismasaprognosticindexoffibrosisprogressioninnafldpatients
AT elsayedmahitab evaluationofabca1genepolymorphismasaprognosticindexoffibrosisprogressioninnafldpatients
AT elsabaawydaliam evaluationofabca1genepolymorphismasaprognosticindexoffibrosisprogressioninnafldpatients
AT elfertashraf evaluationofabca1genepolymorphismasaprognosticindexoffibrosisprogressioninnafldpatients